 | Analysts Anticipate Halozyme Therapeutics, Inc. (NASDAQ:HALO) Will Announce Earnings of $0.32 Per Share
americanbankingnews.com - March 4 at 10:16 PM |
 | Let's Take Another Look at Halozyme Therapeutics
finance.yahoo.com - March 4 at 5:09 PM |
| 2 Overvalued Biotech Stocks Still Worth Buying
finance.yahoo.com - March 4 at 7:04 AM |
| Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 6.8%
americanbankingnews.com - March 3 at 8:06 PM |
| Helen Torley Sells 50,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock
americanbankingnews.com - March 1 at 10:04 PM |
| Michael J. Labarre Sells 18,324 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock
americanbankingnews.com - March 1 at 10:04 PM |
| Kenneth J. Kelley Sells 5,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock
americanbankingnews.com - March 1 at 9:32 PM |
| Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8%
americanbankingnews.com - February 25 at 9:18 PM |
| Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027
finance.yahoo.com - February 24 at 11:11 PM |
 | Why Halozyme Therapeutics Is Trading 14% Higher Today
fool.com - February 24 at 3:45 PM |
|
 | Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls
nasdaq.com - February 24 at 1:10 PM |
| Halozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High at $55.55
americanbankingnews.com - February 24 at 11:01 AM |
| Halozyme Therapeutics Inc (HALO) Q4 2020 Earnings Call Transcript
fool.com - February 23 at 10:44 PM |
| Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results
finance.yahoo.com - February 23 at 7:55 PM |
| Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
finance.yahoo.com - February 23 at 7:55 PM |
| Recap: Halozyme Therapeutics Q4 Earnings
finance.yahoo.com - February 23 at 7:55 PM |
 | Halozyme Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 23 at 7:34 PM |
| Halozyme Therapeutics's Earnings: A Preview
finance.yahoo.com - February 22 at 1:30 PM |
| Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call
finance.yahoo.com - February 10 at 5:57 PM |
 | Antidiabetics Market (Impact of COVID-19) Size, Status and Forecast 2020-2025
marketwatch.com - February 9 at 8:01 PM |
| Halozyme Therapeutics (NASDAQ:HALO) Hits New 1-Year High at $51.28
americanbankingnews.com - February 9 at 10:44 AM |
| Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis
finance.yahoo.com - January 16 at 4:20 AM |
| First Week of September 17th Options Trading For Halozyme Therapeutics (HALO)
nasdaq.com - January 15 at 12:50 PM |
| Regeneron (REGN), U.S. Government Ink Deal for COVID-19 Treatment
finance.yahoo.com - January 13 at 6:12 PM |
 | Sarepta (SRPT) Looks Good: Stock Adds 9.1% in Session
msn.com - January 12 at 1:42 PM |
| Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth
finance.yahoo.com - January 11 at 9:57 AM |
| Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:18 AM |
| A Technical Update on Halozyme Therapeutics
finance.yahoo.com - December 23 at 4:05 PM |
 | Breast Cancer Therapeutics Drugs Market 2021 Growth After Covid-19 Pandemic with Top Manufacturers: Bayer HealthCare, Eli Lily, Pfizer
benzinga.com - December 22 at 8:49 AM |
| Is Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) 22% ROE Better Than Average?
finance.yahoo.com - December 19 at 12:45 PM |
|
| Why These 3 Health Care Stocks Are Moving Today
benzinga.com - December 17 at 1:47 PM |
 | Halozyme Therapeutics (NASDAQ:HALO) Now Covered by Analysts at Berenberg Bank
americanbankingnews.com - December 17 at 8:44 AM |
| Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?
finance.yahoo.com - December 16 at 1:46 PM |
| Viatris (VTRS) to Cut Jobs as Part of Restructuring Initiative
finance.yahoo.com - December 14 at 5:41 PM |
| Exelixis (EXEL) In-Licenses Aurigene's Compound, Files IND
finance.yahoo.com - December 8 at 4:35 PM |
| Halozyme: 7 Years Of Royalty Bliss Coming; Afterwards, Questions To Answer
seekingalpha.com - December 7 at 2:48 AM |
| Halozyme Therapeutics Is Likely to Continue Its Advance
finance.yahoo.com - December 4 at 5:11 PM |
| Why Is Halozyme Therapeutics (HALO) Up 28.4% Since Last Earnings Report?
finance.yahoo.com - December 2 at 4:58 PM |
| What Makes Halozyme Therapeutics (HALO) a Strong Momentum Stock: Buy Now?
finance.yahoo.com - November 27 at 1:47 PM |
| A Look Into Halozyme Therapeutics's Debt
finance.yahoo.com - November 23 at 1:52 PM |
 | Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE ® Technology
businesswire.com - November 23 at 8:51 AM |
| Halozyme raises FY20 guidance on Horizon Therapeutics global collaboration
seekingalpha.com - November 23 at 8:51 AM |
| Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
finance.yahoo.com - November 23 at 8:51 AM |
| Halozyme Raises Full Year 2020 Guidance
finance.yahoo.com - November 23 at 8:51 AM |
| Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference
finance.yahoo.com - November 18 at 8:44 PM |
| Wells Fargo Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $60
benzinga.com - November 17 at 10:54 PM |
 | Thinking about trading options or stock in Ford, Draftkings, Li Auto, Vipshop Holdings, or Halozyme Therapeutics?
prnewswire.com - November 13 at 1:13 PM |
| Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Positive Breast Cancer
finance.yahoo.com - November 13 at 1:13 PM |
| Halozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO™/ DARZALEX® Subcutaneous (SC) Formulation Utilizing ENHANZE® Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma
finance.yahoo.com - November 12 at 1:09 PM |
| Stock Alert: Halozyme Therapeutics Gains 10%
nasdaq.com - November 6 at 1:33 PM |
